JP2007501243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007501243A5 JP2007501243A5 JP2006522651A JP2006522651A JP2007501243A5 JP 2007501243 A5 JP2007501243 A5 JP 2007501243A5 JP 2006522651 A JP2006522651 A JP 2006522651A JP 2006522651 A JP2006522651 A JP 2006522651A JP 2007501243 A5 JP2007501243 A5 JP 2007501243A5
- Authority
- JP
- Japan
- Prior art keywords
- patient weight
- therapeutic agent
- patient
- weight
- ctla4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100005310 CTLA4 Human genes 0.000 claims 30
- 101700054183 CTLA4 Proteins 0.000 claims 30
- 239000003814 drug Substances 0.000 claims 29
- 230000037396 body weight Effects 0.000 claims 13
- 208000007718 Stable Angina Diseases 0.000 claims 7
- 235000004279 alanine Nutrition 0.000 claims 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-Methionine Natural products CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 6
- 208000010125 Myocardial Infarction Diseases 0.000 claims 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 6
- 206010002388 Angina unstable Diseases 0.000 claims 5
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 5
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 5
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 5
- 102000018358 Immunoglobulins Human genes 0.000 claims 5
- 108060003951 Immunoglobulins Proteins 0.000 claims 5
- 208000007814 Unstable Angina Diseases 0.000 claims 5
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 5
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 4
- 201000008739 coronary artery disease Diseases 0.000 claims 4
- 230000002757 inflammatory Effects 0.000 claims 4
- 239000003550 marker Substances 0.000 claims 4
- 206010000891 Acute myocardial infarction Diseases 0.000 claims 3
- 229960005261 Aspartic Acid Drugs 0.000 claims 3
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 3
- 102000005738 B7 Antigens Human genes 0.000 claims 3
- 108010045634 B7 Antigens Proteins 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 235000003704 aspartic acid Nutrition 0.000 claims 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 230000003993 interaction Effects 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 102100019461 CD28 Human genes 0.000 claims 2
- 101700033362 CD28 Proteins 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 claims 2
- 208000006117 ST Elevation Myocardial Infarction Diseases 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000001320 atherosclerosis Diseases 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000000306 recurrent Effects 0.000 claims 2
- 206010003230 Arteritis Diseases 0.000 claims 1
- 229940009098 Aspartate Drugs 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 102400000432 CD40 ligand, soluble form Human genes 0.000 claims 1
- 101800000267 CD40 ligand, soluble form Proteins 0.000 claims 1
- 102100003729 CD40LG Human genes 0.000 claims 1
- 206010061744 Carotid artery disease Diseases 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 210000004351 Coronary Vessels Anatomy 0.000 claims 1
- 229940012952 Fibrinogen Drugs 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- 210000000265 Leukocytes Anatomy 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 210000004165 Myocardium Anatomy 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 206010062585 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 102000011763 Serum Amyloid A Protein Human genes 0.000 claims 1
- 108010076895 Serum Amyloid A Protein Proteins 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000001404 mediated Effects 0.000 claims 1
- 200000000008 restenosis Diseases 0.000 claims 1
- 125000003607 serino group Chemical group [H]OC(=O)C([H])(N([H])*)C([H])([H])O[H] 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
Claims (29)
- Ｂ７とＣＴＬＡ４および／またはＣＤ２８の相互作用を遮断する分子の有効量を含む、心臓血管疾患の治療剤。
- Ｂ７とＣＴＬＡ４および／またはＣＤ２８の相互作用を遮断する分子が、可溶性ＣＴＬＡ４分子である、請求項１の治療剤。
- 該心臓血管疾患が、アテローム性動脈硬化症；心臓冠状動脈疾患（ＣＨＤ）；再狭窄；末梢動脈疾患；冠状動脈バイパス手術；頸動脈疾患；動脈炎；心筋炎；心臓血管炎；血管炎；不安定狭心症（ＵＡ）；難治性不安定狭心症；安定狭心症（ＳＡ）；慢性安定狭心症；急性冠状動脈症候群（ＡＣＳ）；心筋梗塞；初期または再発心筋梗塞を含む急性心筋梗塞（ＡＭＩ）、非Ｑ波心筋梗塞、非ＳＴ上昇心筋梗塞およびＳＴ上昇心筋梗塞からなる群から選択される、請求項１の治療剤。
- 該心臓血管疾患が、アテローム性動脈硬化症；心臓冠状動脈疾患（ＣＨＤ）；不安定狭心症（ＵＡ）；難治性不安定狭心症；安定狭心症（ＳＡ）；慢性安定狭心症；急性冠状動脈症候群（ＡＣＳ）；心筋梗塞；初期または再発心筋梗塞を含む急性心筋梗塞（ＡＭＩ）、非Ｑ波心筋梗塞、非ＳＴ上昇心筋梗塞およびＳＴ上昇心筋梗塞からなる群から選択される、請求項３の治療剤。
- 該心臓血管疾患が、Ｔ細胞とＢ７陽性細胞の相互作用によって介在される、請求項１の治療剤。
- 該心臓血管疾患が、少なくとも一つの炎症マーカーと関連する、請求項１の治療剤。
- 該炎症マーカーが、ＣＲＰ、ｈｓＣＲＰ、ＩＬ−１０、ＣＤ４０Ｌ、ｓＣＤ４０Ｌ、ＩＬ−６、ｓＩＣＡＭ−１、ＴＮＦ−α、白血球数、フィブリノーゲン、および血清アミロイドＡからなる群から選択される、請求項６の治療剤。
- 該炎症マーカーが、ＣＲＰ、ｈｓＣＲＰ、ＩＬ−６、およびＴＮＦ−αからなる群から選択される、請求項７の治療剤。
- 該可溶性ＣＴＬＡ４分子の有効量が、約０．１〜１００ｍｇ／ｋｇ（患者の体重）、約０．５〜１００ｍｇ／ｋｇ（患者の体重）、０．５〜５ｍｇ／ｋｇ（患者の体重）、約５〜１０ｍｇ／ｋｇ（患者の体重）、約１０〜１５ｍｇ／ｋｇ（患者の体重）、約１５〜２０ｍｇ／ｋｇ（患者の体重）、約２０〜２５ｍｇ／ｋｇ（患者の体重）、約２５〜３０ｍｇ／ｋｇ（患者の体重）、約３０〜３５ｍｇ／ｋｇ（患者の体重）、約３５〜４０ｍｇ／ｋｇ（患者の体重）、約４０〜４５ｍｇ／ｋｇ（患者の体重）、約４５〜５０ｍｇ／ｋｇ（患者の体重）、約５０〜５５ｍｇ／ｋｇ（患者の体重）、約５５〜６０ｍｇ／ｋｇ（患者の体重）、約６０〜６５ｍｇ／ｋｇ（患者の体重）、約６５〜７０ｍｇ／ｋｇ（患者の体重）、約７０〜７５ｍｇ／ｋｇ（患者の体重）、約７５〜８０ｍｇ／ｋｇ（患者の体重）、約８０〜８５ｍｇ／ｋｇ（患者の体重）、約８５〜９０ｍｇ／ｋｇ（患者の体重）、約９０〜９５ｍｇ／ｋｇ（患者の体重）、約９５〜１００ｍｇ／ｋｇ（患者の体重）、約２〜１０ｍｇ／ｋｇ（患者の体重）、約０．１〜４ｍｇ／ｋｇ（患者の体重）、約０．１〜０．５ｍｇ／ｋｇ（患者の体重）、約０．５〜１．０ｍｇ／ｋｇ（患者の体重）、約１．０〜１．５ｍｇ／ｋｇ（患者の体重）、約１．５〜２．０ｍｇ／ｋｇ（患者の体重）、約２．０〜２．５ｍｇ／ｋｇ（患者の体重）、約２．５〜３．０ｍｇ／ｋｇ（患者の体重）、約３．０〜３．５ｍｇ／ｋｇ（患者の体重）、約３．５〜４．０ｍｇ／ｋｇ（患者の体重）、約４．０〜４．５ｍｇ／ｋｇ（患者の体重）、約４．５〜５．０ｍｇ／ｋｇ（患者の体重）、約５．０〜５．５ｍｇ／ｋｇ（患者の体重）、約５．５〜６．０ｍｇ／ｋｇ（患者の体重）、約６．０〜６．５ｍｇ／ｋｇ（患者の体重）、約６．５〜７．０ｍｇ／ｋｇ（患者の体重）、約７．０〜７．５ｍｇ／ｋｇ（患者の体重）、約７．５〜８．０ｍｇ／ｋｇ（患者の体重）、約８．０〜８．５ｍｇ／ｋｇ（患者の体重）、約８．５〜９．０ｍｇ／ｋｇ（患者の体重）、約９．０〜９．５ｍｇ／ｋｇ（患者の体重）、約９．５〜１０．０ｍｇ／ｋｇ（患者の体重）、約０．１〜２ｍｇ／ｋｇ（患者の体重）、約２〜４ｍｇ／ｋｇ（患者の体重）、約４〜６ｍｇ／ｋｇ（患者の体重）、約６〜８ｍｇ／ｋｇ（患者の体重）、約８〜１０ｍｇ／ｋｇ（患者の体重）、約１０〜１２ｍｇ／ｋｇ（患者の体重）、約１２〜１４ｍｇ／ｋｇ（患者の体重）、約１４〜１６ｍｇ／ｋｇ（患者の体重）、約１６〜１８ｍｇ／ｋｇ（患者の体重）、約１８〜２０ｍｇ／ｋｇ（患者の体重）、約０．５ｍｇ／ｋｇ（患者の体重）、２ｍｇ／ｋｇ（患者の体重）、１０ｍｇ／ｋｇ（患者の体重）、約０．５〜１００ｍｇ／ｋｇ（患者の体重）、約０．５〜１０ｍｇ／ｋｇ（患者の体重）、約０．１〜２０ｍｇ／ｋｇ（患者の体重）、６０ｋｇ以下の患者に対して約５００ｍｇ、６０〜１００ｋｇの患者に対して７５０ｍｇ、または１００ｋｇ以上の患者に対して１０００ｍｇである、請求項２の治療剤。
- 該可溶性ＣＴＬＡ４分子が、活性化したＢ細胞で発現されたＢ７抗原と結合するＣＴＬＡ４分子の細胞外ドメインまたはその一部分を含む、請求項２の治療剤。
- 該ＣＴＬＡ４分子の細胞外ドメインが、＋１位のメチオニンまたは−１位のアラニンで始まり、１２４位のアスパラギン酸で終わる図２３で示すアミノ酸を含む、請求項１０の治療剤。
- 該可溶性ＣＴＬＡ４分子がＣＴＬＡ４融合分子である、請求項２の治療剤。
- 該ＣＴＬＡ４融合分子が、非ＣＴＬＡ４分子と結合した活性化されたＢ細胞で発現されるＢ７抗原と結合するＣＴＬＡ４分子の細胞外ドメインを含む、請求項１１の治療剤。
- 該ＣＴＬＡ４分子の細胞外ドメインが、＋１位のメチオニンまたは−１位のアラニンで始まり、１２４位のアスパラギン酸で終わる図２３で示すアミノ酸を含む、請求項１３の治療剤。
- 該非ＣＴＬＡ４分子が、可溶性ＣＴＬＡ４分子の溶解性または親和性を変えるアミノ酸配列を含む、請求項１３の治療剤。
- 該溶解性または親和性を変えるアミノ酸配列が免疫グロブリン部分を含む、請求項１５の治療剤。
- 該免疫グロブリン部分が、エフェクター機能を減少するために、１またはそれ以上の突然変異を含む、請求項１６の治療剤。
- 該免疫グロブリン部分がヒンジを含み、該ヒンジ内のシステイン残基のいずれかまたはすべてがセリンで置換される、請求項１６の治療剤。
- 該免疫グロブリン部分が、免疫グロブリンの定常領域またはその一部である、請求項１６の治療剤。
- 該免疫グロブリン定常領域またはその一部が、エフェクター機能を減少するために突然変異する、請求項１９の治療剤。
- 該免疫グロブリン定常領域が、免疫グロブリン分子のヒンジ、ＣＨ２およびＣＨ３領域を含む、請求項１９の治療剤。
- 該免疫グロブリン定常領域またはその一部が、ヒトまたはサルの免疫グロブリン定常領域またはその一部である、請求項１９の治療剤。
- 該ＣＴＬＡ４融合分子がＣＴＬＡ４Ｉｇである、請求項１２の治療剤。
- 該ＣＴＬＡ４Ｉｇが、＋１位のメチオニンまたは−１位のアラニンで始まり、＋３５７位のリジンで終わる図２４で示される、請求項２３の治療剤。
- 該可溶性ＣＴＬＡ４分子が、可溶性ＣＴＬＡ４の突然変異分子である、請求項２の治療剤。
- 該可溶性ＣＴＬＡ４の突然変異分子が、活性化されたＢ細胞で発現されたＢ７抗原と結合し、ＣＴＬＡ４分子の細胞外ドメイン中に突然変異を含む、請求項２５の治療剤。
- 該可溶性ＣＴＬＡ４の突然変異分子が、ＣＴＬＡ４の細胞外ドメインを含み、
ａ）該ＣＴＬＡ４の細胞外ドメインが、図２３で示すとおり、＋１位のメチオニンまたは−１位のアラニンで始まり、＋１２４位のアスパラギン酸で終わり、および
ｂ）該ＣＴＬＡ４の細胞外ドメインの＋１０４位で、ロイシンが他のいずれかのアミノ酸で置換される、請求項２５の治療剤。 - 該可溶性ＣＴＬＡ４の突然変異分子が、ＣＴＬＡ４の細胞外ドメインを含み、
ａ）該ＣＴＬＡ４の細胞外ドメインが、図２３で示すとおり、＋１位のメチオニンまたは−１位のアラニンで始まり、＋１２４位のアスパラギン酸で終わり；
ｂ）該ＣＴＬＡ４の細胞外ドメインの＋１０４位で、ロイシンがグルタミン酸で置換され；および
ｃ）該ＣＴＬＡ４の細胞外ドメインの＋２９位で、アラニンがチロシンで置換される、請求項２５の治療剤。 - 該可溶性ＣＴＬＡ４の突然変異分子が、図１９で示すとおり、＋１位のメチオニンまたは−１位のアラニンで始まり、＋３５７位のリジンで終わる、Ｌ１０４ＥＡ２９ＹＩｇである、請求項２５の治療剤。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49243003P | 2003-08-04 | 2003-08-04 | |
| PCT/US2004/024840 WO2005016266A2 (en) | 2003-08-04 | 2004-08-03 | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007501243A JP2007501243A (ja) | 2007-01-25 |
| JP2007501243A5 true JP2007501243A5 (ja) | 2007-07-05 |
Family
ID=34193123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006522651A Pending JP2007501243A (ja) | 2003-08-04 | 2004-08-03 | 可溶性ｃｔｌａ４分子を用いる心臓血管疾患の治療方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7307064B2 (ja) |
| EP (1) | EP1670499A4 (ja) |
| JP (1) | JP2007501243A (ja) |
| KR (2) | KR20090087514A (ja) |
| CN (1) | CN1863546A (ja) |
| AU (2) | AU2004264901B2 (ja) |
| BR (1) | BRPI0413326A (ja) |
| CA (2) | CA2762015A1 (ja) |
| MX (1) | MXPA06001225A (ja) |
| NO (1) | NO20060477L (ja) |
| NZ (2) | NZ545314A (ja) |
| RU (1) | RU2353384C2 (ja) |
| SG (1) | SG144925A1 (ja) |
| WO (1) | WO2005016266A2 (ja) |
| ZA (1) | ZA200601031B (ja) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
| US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| ATE390931T1 (de) | 2001-05-23 | 2008-04-15 | Bristol Myers Squibb Co | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen |
| PL377731A1 (pl) | 2002-12-23 | 2006-02-06 | Bristol-Myers Squibb Company | Sposoby hodowli komórek ssaczych do wytwarzania białka |
| PT1576182E (pt) | 2002-12-23 | 2011-01-21 | Bristol Myers Squibb Co | Optimizador da qualidade do produto em processos de cultura celular de mamíferos destinados à produção de proteínas |
| SG144925A1 (en) * | 2003-08-04 | 2008-08-28 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| PL2253644T3 (pl) | 2005-12-20 | 2014-04-30 | Bristol Myers Squibb Co | Kompozycje i sposoby wytwarzania kompozycji |
| PL1962886T6 (pl) * | 2005-12-20 | 2023-03-13 | Bristol-Myers Squibb Company | Stabilne formulacje białkowe |
| US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
| PT2222697E (pt) * | 2007-11-01 | 2013-02-15 | Perseid Therapeutics Llc | Polipeptídeos imunossupressores e ácidos nucleicos |
| US7915222B2 (en) * | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| PT2344540T (pt) | 2008-10-02 | 2018-02-02 | Aptevo Res & Development Llc | Proteínas de ligação multi-alvo antagonistas de cd86 |
| CN102271702B (zh) * | 2008-10-30 | 2015-11-25 | 耶达研究及发展有限公司 | 抗第三方中枢记忆性t细胞、产生其的方法及其在移植和疾病治疗中的用途 |
| EP2550021A2 (en) * | 2010-03-22 | 2013-01-30 | Association Institut de Myologie | Methods of increasing efficiency of vector penetration of target tissue |
| HUE031063T2 (en) | 2010-09-08 | 2017-06-28 | Yeda Res & Dev | Anti-third party use of central memory T cells for leukemia / anti-lymphoma treatment |
| CA2810631A1 (en) | 2010-09-08 | 2012-03-15 | Yeda Research And Development Co. Ltd. | An immunosuppressive drug combination for a stable and long term engraftment |
| CN102109517A (zh) * | 2010-12-14 | 2011-06-29 | 邵棠 | 心脑血管疾病生物标志物的联合检测方法及诊断试剂盒 |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| BR112014005355B1 (pt) | 2011-09-08 | 2022-03-29 | Yeda Research An Development Co., Ltd | Células t de memória central anti-terceiro, métodos de produção e uso das mesmas em transplante e tratamento de doença |
| CN102786433B (zh) * | 2012-03-15 | 2016-09-21 | 浙江康恩贝制药股份有限公司 | 一种延胡索酰胺类化合物提取物及其制备方法和应用 |
| CA2889182A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| CN103175959B (zh) * | 2013-02-28 | 2015-10-14 | 成都创宜生物科技有限公司 | 一种检测胎膜早破免疫层析试纸的制备方法 |
| JP6574414B2 (ja) | 2013-06-07 | 2019-09-11 | アレナ ファーマシューティカルズ， インコーポレイテッド | 透析のための組成物、方法、および器具 |
| EP2883883A1 (en) | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutic targets and agents useful in treating ischemia reperfusion injury |
| DK3283508T3 (en) | 2015-04-17 | 2021-05-31 | Alpine Immune Sciences Inc | Immunomodulatory Proteins with Tunable Affinities |
| DK3322425T3 (da) | 2015-07-16 | 2023-06-12 | Yeda Res & Dev | Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi |
| TW201722985A (zh) | 2015-11-02 | 2017-07-01 | 戊瑞治療有限公司 | Cd80胞外域多肽及其用於癌症治療 |
| EP3192805A1 (en) * | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
| EP3571295A1 (en) | 2017-01-18 | 2019-11-27 | Yeda Research and Development Co. Ltd | Genetically modified veto cells and use of same in immunotherapy |
| US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
| EP3628070B1 (en) | 2017-04-28 | 2021-09-08 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides for use in increasing central memory t cells |
| EP3694870A1 (en) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| GB201809050D0 (en) | 2018-06-01 | 2018-07-18 | E Therapeutics Plc | Modulators of tryptophan catabolism |
| DK3920970T3 (da) | 2019-02-04 | 2023-01-23 | Hopitaux Paris Assist Publique | Fremgangsmåde til behandling af utilsigtede hændelser induceret af checkpoint-hæmmere |
| US20210038684A1 (en) | 2019-06-11 | 2021-02-11 | Alkermes Pharma Ireland Limited | Compositions and Methods for Cancer Immunotherapy |
| JP2022549227A (ja) | 2019-09-17 | 2022-11-24 | バイアル－アールアンドディー インベストメンツ ソシエダッド アノニマ | 医学的障害の治療における使用のための置換された飽和および不飽和ｎ－複素環式カルボキサミドおよび関連化合物 |
| US20220402901A1 (en) | 2019-09-17 | 2022-12-22 | Bial - R&D Investments, S.A. | Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments |
| AU2020349516A1 (en) | 2019-09-17 | 2022-03-17 | Bial-R&D Investments, S.A. | Substituted imidazole carboxamides and their use in the treatment of medical disorders |
| JP2023517011A (ja) | 2020-03-05 | 2023-04-21 | ネオティーエックス セラピューティクス リミテッド | 免疫細胞を用いて癌を治療するための方法および組成物 |
| EP4256067A2 (en) | 2020-12-04 | 2023-10-11 | Tidal Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
| MX2024002281A (es) | 2021-08-23 | 2024-05-20 | Immunitas Therapeutics Inc | Anticuerpos anti-cd161 y usos de los mismos. |
| WO2023112992A1 (ja) * | 2021-12-16 | 2023-06-22 | レグセル株式会社 | 免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物 |
| WO2023240156A1 (en) | 2022-06-08 | 2023-12-14 | Tidal Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
| WO2024086827A2 (en) | 2022-10-20 | 2024-04-25 | Repertoire Immune Medicines, Inc. | Cd8 t cell targeted il2 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2003455C (en) | 1988-11-23 | 2000-02-22 | Craig B. Thompson | Immunotherapy involving cd28 stimulation |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6685941B1 (en) | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
| WO1993019767A1 (en) | 1992-04-07 | 1993-10-14 | The Regents Of The University Of Michigan | Cd28 pathway immunoregulation |
| US7070776B1 (en) * | 1990-03-26 | 2006-07-04 | Bristol-Myers Squibb Company | Methods for blocking binding of CD28 receptor to B7 |
| US5580756A (en) * | 1990-03-26 | 1996-12-03 | Bristol-Myers Squibb Co. | B7Ig fusion protein |
| US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
| US6090914A (en) * | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
| US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5844095A (en) * | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| KR100238712B1 (ko) * | 1991-06-27 | 2000-01-15 | 스티븐 비. 데이비스 | 씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도 |
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5420653A (en) * | 1992-01-06 | 1995-05-30 | Mumford; Robin B. | Method and apparatus for the amelioration of visual stress and dyslexia |
| US5773253A (en) * | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| AU7107794A (en) | 1993-06-10 | 1995-01-03 | Regents Of The University Of Michigan, The | Cd28 pathway immunosuppression |
| EP0812692B1 (en) * | 1993-12-28 | 2001-11-07 | Seiko Epson Corporation | Ink jet recording head |
| US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
| US6113898A (en) * | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US5916560A (en) * | 1996-03-20 | 1999-06-29 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith |
| US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
| ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
| DE19948126A1 (de) * | 1999-10-06 | 2001-04-12 | Max Delbrueck Centrum | Pharmazeutisches Mittel zur Behandlung von Kachexie und/oder kardiogenem Schock |
| US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| CN1438894A (zh) * | 2000-06-09 | 2003-08-27 | 布里斯托尔-迈尔斯斯奎布公司 | 通过阻断淋巴细胞信号和阻断lfa－1介导的粘附作用调节细胞介导的免疫应答的方法 |
| US20040022787A1 (en) * | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| EP2281568A3 (en) * | 2000-07-03 | 2013-04-24 | Bristol-Myers Squibb Company | Uses of soluble CTLA4 mutant molecules |
| PL375139A1 (en) * | 2001-01-26 | 2005-11-28 | Emory University | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| ATE390931T1 (de) * | 2001-05-23 | 2008-04-15 | Bristol Myers Squibb Co | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen |
| ES2535365T3 (es) * | 2002-07-19 | 2015-05-08 | Abbott Biotechnology Ltd. | Tratamiento de trastornos relacionados con TNF alfa |
| PL377731A1 (pl) | 2002-12-23 | 2006-02-06 | Bristol-Myers Squibb Company | Sposoby hodowli komórek ssaczych do wytwarzania białka |
| PT1576182E (pt) | 2002-12-23 | 2011-01-21 | Bristol Myers Squibb Co | Optimizador da qualidade do produto em processos de cultura celular de mamíferos destinados à produção de proteínas |
| SG144925A1 (en) * | 2003-08-04 | 2008-08-28 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
-
2004
- 2004-08-03 SG SG200805216-9A patent/SG144925A1/en unknown
- 2004-08-03 US US10/910,531 patent/US7307064B2/en not_active Expired - Lifetime
- 2004-08-03 MX MXPA06001225A patent/MXPA06001225A/es active IP Right Grant
- 2004-08-03 NZ NZ545314A patent/NZ545314A/en not_active IP Right Cessation
- 2004-08-03 RU RU2006106636/14A patent/RU2353384C2/ru not_active IP Right Cessation
- 2004-08-03 WO PCT/US2004/024840 patent/WO2005016266A2/en active Application Filing
- 2004-08-03 BR BRPI0413326-9A patent/BRPI0413326A/pt not_active Application Discontinuation
- 2004-08-03 CA CA2762015A patent/CA2762015A1/en not_active Abandoned
- 2004-08-03 NZ NZ573652A patent/NZ573652A/en not_active IP Right Cessation
- 2004-08-03 KR KR1020097016161A patent/KR20090087514A/ko not_active Application Discontinuation
- 2004-08-03 CN CNA2004800289603A patent/CN1863546A/zh active Pending
- 2004-08-03 CA CA2534474A patent/CA2534474C/en not_active Expired - Fee Related
- 2004-08-03 EP EP04779791A patent/EP1670499A4/en not_active Withdrawn
- 2004-08-03 JP JP2006522651A patent/JP2007501243A/ja active Pending
- 2004-08-03 KR KR1020067002436A patent/KR20060132541A/ko not_active Application Discontinuation
- 2004-08-03 AU AU2004264901A patent/AU2004264901B2/en not_active Ceased
-
2006
- 2006-01-30 NO NO20060477A patent/NO20060477L/no not_active Application Discontinuation
- 2006-02-03 ZA ZA200601031A patent/ZA200601031B/en unknown
-
2007
- 2007-08-14 US US11/892,000 patent/US7671022B2/en active Active
- 2007-10-19 US US11/975,659 patent/US20090041790A1/en not_active Abandoned
-
2009
- 2009-12-01 AU AU2009243460A patent/AU2009243460B9/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007501243A5 (ja) | ||
| RU2006106636A (ru) | Способ лечения кардиоваскулярных заболеваний | |
| JP4698579B2 (ja) | 可逆的ｐｅｇ化薬物 | |
| JP5878757B2 (ja) | Ｆｇｆ２１変異体およびその使用 | |
| ES2397852T3 (es) | Antagonistas y conjugados de péptidos CGRP | |
| JP4750360B2 (ja) | 抗体ターゲッティング化合物 | |
| JP5280683B2 (ja) | ペプチド系化合物 | |
| JP2016504335A (ja) | Ａｐｊ受容体アゴニストおよびその使用 | |
| JP2012518029A (ja) | 第ｖｉｉｉ因子の修飾 | |
| TNSN07031A1 (fr) | Anticorps diriges contre le peptide amyloide-beta et methodes pour leur utilisation | |
| EA019203B1 (ru) | Коагонисты глюкагонового рецептора/glp-1-рецептора | |
| MX2010013453A (es) | Agonistas mezclados basados en gip para el tratamiento de desordenes metabolicos y obesidad. | |
| EP3380525A1 (en) | Pharmaceutical formulations and methods of use thereof | |
| CA2296711A1 (fr) | Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique | |
| EP2161284B1 (en) | Citrulinated fibrin-filaggrin chimeric polypeptide capable of detecting the antibodies generated in rheumatoid arthritis | |
| JP2024099564A (ja) | 凝集体を標的とし、一掃するためのコンジュゲート | |
| BRPI0308376B1 (pt) | Molécula de anticorpo anti-ED-B humana, seu uso e composição | |
| JP2022082754A (ja) | Ｖｅｇｆのためのｄ－ペプチド性化合物 | |
| Kameyama et al. | Effects of cell-permeating peptide binding on the distribution of 125I-labeled Fab fragment in rats | |
| BRPI0915968A2 (pt) | método para o tratamento de infecções com febre da dengue imunomediada e intensificação dependente de anticorpos de infecções com febre da dengue, incluindo febre hemorrágia e sídrome de choque da dengue | |
| Bridger et al. | A comparison of cleavable and noncleavable hydrazinopyridine linkers for the 99mTc labeling of Fab ‘monoclonal antibody fragments | |
| TW202204336A (zh) | 標靶tem-1之放射免疫結合物及其用途 | |
| Arano et al. | Assessment of radiochemical design of antibodies using an ester bond as the metabolizable linkage: evaluation of maleimidoethyl 3-(tri-n-butylstannyl) hippurate as a radioiodination reagent of antibodies for diagnostic and therapeutic applications | |
| JP2003507711A (ja) | 免疫検定用の２個のエピトープを保持する合成化合物 | |
| JP2009242372A (ja) | 均一な糖鎖構造を有するエリスロポエチン誘導体 |